A radio signal from the beginning of the universe could reveal how everything began
The signal – known as the 21-centimetre signal – could finally let us understand how the first stars and galaxies switched on, and brought the universe from darkness to light.
'This is a unique opportunity to learn how the universe's first light emerged from the darkness,' said co-author Anastasia Fialkov from Cambridge University, in a statement. 'The transition from a cold, dark universe to one filled with stars is a story we're only beginning to understand.'
The signal comes to us from more than 13 billion years ago, just a hundred million years after the Big Bang. The faint glow is created by hydrogen atoms that fill up the space between regions of space where stars are being formed.
Scientists now believe they will be able to use the nature of that signal to better understand the early universe. They will do that with a radio antenna called REACH – the Radio Experiment for the Analysis of Cosmic Hydrogen – which will try and capture radio signals to reveal data about the beginnings of the universe.
To better understand how that project might work, researchers created a model that predicted how REACH as well as another project called the Square Kilometre Array will be able to provide information about the masses and other details of the first stars.
'We are the first group to consistently model the dependence of the 21-centimetre signal of the masses of the first stars, including the impact of ultraviolet starlight and X-ray emissions from X-ray binaries produced when the first stars die,' said Professor Fialkov.
'These insights are derived from simulations that integrate the primordial conditions of the universe, such as the hydrogen-helium composition produced by the Big Bang.'
'The predictions we are reporting have huge implications for our understanding of the nature of the very first stars in the Universe,' said co-author Eloy de Lera Acedo, Principal Investigator of the REACH telescope.
'We show evidence that our radio telescopes can tell us details about the mass of those first stars and how these early lights may have been very different from today's stars.
'Radio telescopes like REACH are promising to unlock the mysteries of the infant Universe, and these predictions are essential to guide the radio observations we are doing from the Karoo, in South Africa.'
The work is described in a new paper, 'Determination of the mass distribution of the first stars from the 21-cm signal', published in the journal Nature Astronomy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 minutes ago
- Medscape
Low Disease Activity Maintained Long Term With TNF Tapering
TOPLINE: A tapering strategy for TNF inhibitors maintained low disease activity in patients with psoriatic arthritis (PsA) and those with axial spondyloarthritis (AxSpA) over 24 months. Protocol-driven tapering achieved a greater reduction in the mean dose of TNF inhibitors than routine care tapering, with both methods equally effective for disease control. METHODOLOGY: Previous 12-month results from an open-label, noninferiority, pragmatic trial (January 2019 to July 2020) conducted in the Netherlands showed that tapering of TNF inhibitors was noninferior to continued dosing for maintaining low disease activity in patients with PsA or AxSpA. Participants in the original trial (aged 16 years or older with stable low disease activity for 6 or more months) were randomly assigned to either a treat-to-target tapering strategy (intervention) or a continuation of the original dose of TNF inhibitors (control). Tapering involved extending the interval between doses, leading to doses equivalent to 100%, 66%, 50%, 33%, or 0% of the defined daily dose. This observational extension of the original trial included 114 patients (mean age, 50 years; 79 from the intervention group and 35 from the control group) with PsA (n = 58) and AxSpA (n = 56), where the intervention group continued the tapering strategy, whereas the control group could attempt tapering (routine care tapering), with treatment decisions made collaboratively by physicians and patients. The primary outcome was the difference in the proportion of patients with low disease activity at 24 months between the intervention and control groups compared against a prespecified noninferiority margin of 20%. Secondary outcomes included differences in efficacy between the intervention and control groups determined using disease activity scores at 18 and 24 months, as well as the cumulative incidence of disease flare over 24 months. TAKEAWAY: At 24 months, 67% of patients in the intervention group and 72% in the control group maintained low disease activity (adjusted difference, 5%; P = .64). Over 24 months, 89% of patients attempted tapering, with no significant differences in adverse events between groups. No difference was noted in the percentage of patients achieving low disease activity between the intervention group with protocol-driven tapering at 12 months and the control group with routine care tapering at 24 months. The cumulative incidence of disease flare was 90% over 24 months. The mean dose of TNF inhibitors increased in the intervention group from 52% to 66% of the defined daily dose from 12 months to 24 months (difference, 14%; P < .0001). However, the mean dose was lower with protocol-driven tapering in the intervention group at 12 months than with routine care tapering in the control group at 24 months (P = .0001) and lower with routine care tapering vs no tapering in the control group (P = .0007). IN PRACTICE: '[T]hese data indicate that a taper-to-target strategy is effective and leads to substantial TNF inhibitor dose reduction, but optimal execution of such a strategy in routine care is more challenging than in the context of a clinical trial,' the authors of the study wrote. 'Considering the risks and benefits of tapering, we suggest that disease activity-guided tapering could enable more optimized and personalized treatment in patients with psoriatic arthritis and axial spondyloarthritis.' SOURCE: The study was led by Amy C.D. Peeters, MD, and Celia A.J. Michielsens, MD, PhD, Sint Maartenskliniek in Nijmegen, the Netherlands. It was published online on July 24, 2025, in The Lancet Rheumatology. LIMITATIONS: Measurements for disease activity were missing at 18 and 24 months. The absence of validated flare criteria until 2022 may have led to an overestimation of flare incidence. Radiographic progression was not assessed at the 24-month follow-up. Allowing tapering in the control group during the extension phase reduced the difference between groups. DISCLOSURES: The study was funded by ReumaNederland. Some authors reported receiving grants from multiple companies including Novartis, Eli Lilly and Company, and AbbVie to their institution. One author reported receiving support for attending meetings and/or travel from Pfizer, Novartis, and UCB. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
33 minutes ago
- Medscape
Implantable Device Shows Promise for Preventing Hypoglycemia
A new minimally invasive device, while still in development, could become a lifesaver for individuals with diabetes who experience hypoglycemia, according to researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. In a paper published in Nature Biomedical Engineering , Siddharth R. Krishnan, PhD, now an assistant professor of electrical engineering at Stanford University in Stanford, California, and colleagues at MIT described a wireless device implanted into diabetic mice that prevented hypoglycemia. The implant weighs < 2 g and is only 3 cm3 in size; it remains under the skin and releases a powdered version of glucagon automatically when a sensor detects low blood sugar. The researchers simulated hypoglycemia in the mice, and the release of the dry glucagon was triggered wirelessly. Measurements showed a rapid rise in blood glucose soon after the release, with a peak of 30 mg/dL after no more than 15 minutes. A second set of studies replicated conditions that often drive hypoglycemia, such as missed meals and automated infusions from insulin pumps. Similarly, the use of the wireless release of dry glucagon resulted in blood glucose concentrations above the threshold for hypoglycemia (average concentration of 80 mg/dL) within the first hour after the release. An area under the curve analysis over 30 minutes after release showed significant changes in the glucose group compared with the control group who received lactose. 'A Pathway to Emergency Rescue' 'Glucagon is widely administered as an emergency rescue drug for patients suffering acute hypoglycemia, particularly in the context of type 1 diabetes,' corresponding author Daniel Anderson, PhD, a professor at the Koch Institute for Integrative Cancer Research at MIT, told Medscape Medical News . Glucagon's short half-life and low stability in solution has made development of pump systems a challenge, he said. By contrast, 'Dry powder versions of glucagon offer long-term stability but are difficult to deliver,' he said. 'An implantable device that can respond to hypoglycemia and release dry powder glucagon potentially offers a pathway to emergency rescue from hypoglycemia events without the need for patient intervention,' Anderson said. The early impact of the dry power was unexpected, Anderson said. 'The glucagon in our system is a dry powder that we designed to dissolve directly in biofluid, and the timeline for this dissolution and subsequent availability of the drug in circulation was an open question when we started this project,' he noted. 'The fact that we saw biological activity within 5 minutes of drug release was an important result in this context, and not one that we predicted.' Although the device is not ready for human use, the size and longevity are key questions for adoption in clinical practice, Anderson told Medscape Medical News . 'We are working on miniaturizing the device, so it is compatible with minimally invasive insertion techniques, and with a sufficient number of doses to provide protection from acute hypoglycemia for multiple years,' he said. 'So far, we have validated the device in preclinical small animal models.' Simultaneously miniaturizing the system and optimizing the dose and longevity in large animal models are the next steps for research, he added. Unmet Need for Glycemic Control 'Hypoglycemia and fear of hypoglycemia remains major barriers to optimal glycemic control for those with diabetes,' said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, Michigan, in an interview. 'Glucagon emergency delivery devices have advanced and become more user friendly but will not work if not available or expired. Liquid glucagon presents numerous challenges and is not yet commercially available for dual hormone insulin pump use,' said Kraftson, who was not involved in the research. 'Dual hormone pumps that are being studied or have been approved in Europe are large/bulky, may require two CGM [continuous glucose monitoring] sensors, and may require glucagon to be refilled more frequently than insulin, so a nonliquid, implantable device could avoid some of the obstacles posed by liquid glucagon,' Kraftson noted. However, more research is needed on the logistics of human implementation of the glucagon delivery device tested in the current study, Kraftson told Medscape Medical News . Questions include how the device would be implanted; how many doses the reservoir would hold; and how often, on average, it would need to be changed, he said. Other factors include how cumbersome this device might be for humans, potential risks for irritation or infection, and options for manual delivery in the event of a malfunctioning CGM or signal challenges in device communication, he said. 'Ideally, glucagon use for patients with diabetes would expand beyond emergency rescue,' Kraftson added. 'Reducing or even holding insulin is sometimes insufficient to avoid hypoglycemia, particularly rapid onset.' 'Additionally, eating carbohydrates to prevent or treat hypoglycemia is not ideal given the risk of subsequent overcorrection/hyperglycemia and weight gain; therefore, more frequent, sensor/algorithm-based use of glucagon can more effectively achieve stable glucose levels and help avoid the 'rollercoaster,'' he said. The small size of the device in the current study may limit its ability to participate in the larger mission of glucose management but could certainly still play an important role in hypoglycemia reduction, he noted. This study was funded by the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health, a JDRF postdoctoral fellowship, and the National Institute of Biomedical Imaging and Bioengineering. Anderson and several coauthors reported being inventors on a patent application relevant to the technology described in this study but had no other financial conflicts of interest.
CNN
an hour ago
- CNN
Testing finds caffeinated coffee is clean of contaminants. Well, almost
That cup of joe that jolts you awake in the morning is pretty safe when it comes to contaminants and toxins, a new investigation has found. Well … almost. 'While some contaminants were present, most were found at minimal levels and well below the European Union's safety limits per 6-ounce serving. This means coffee is generally safe,' said Molly Hamilton, executive director of the nonprofit Clean Label Project, which conducted the investigation into caffeinated coffees. That's great news because coffee has a stellar résumé: Studies have found drinking about 3 cups of black coffee a day provides health benefits, such as reducing risk for such issues as heart disease, multiple sclerosis, type 2 diabetes, liver disease, prostate cancer, stroke, dementia and more. But here's the grind — the testing found traces of a worrisome herbicide called glyphosate and one of its byproducts. Glyphosate is a popular herbicide that has been linked to hormone disruptions and neurotoxic effects, including the development of autism and other developmental disorders in children. The first MAHA (Make America Healthy Again) Commission report, released in May, raised concerns about the impact of glyphosate and other pesticides on children's health. The US Environmental Protection Agency and other regulatory bodies, however, say numerous studies and risk assessments have shown no adverse effects of glyphosate at levels found in the food supply. In addition to glyphosate, testing found some coffees also contained small amounts of phthalates, a plasticizer found in consumer products such as food storage containers, shampoo, makeup, perfume and children's toys. Phthalates have been linked with reproductive problems, such as genital malformations and undescended testes in baby boys and lower sperm counts and testosterone levels in adult males. Studies have also linked phthalates to asthma, childhood obesity and cancer. Testing found the highest levels of phthalates in coffee sold in cans, followed by pods and finally bags. The reason for that isn't yet clear, 'so our next study is going to be analyzing the packaging assembly line to discover why there is a change in contaminants,' Hamilton said. 'The Clean Label Project plays an important role in post-market testing for contaminants in everyday consumer products, including this recent report on coffee,' said David Andrews, acting chief science officer for the Environmental Working Group, or EWG, a nonprofit consumer advocacy group that maintains a database on personal care products that contain toxins. 'The higher phthalate levels found in coffee pods and canned coffee suggest that packaging could be a meaningful source of exposure to these chemicals of concern,' Andrews said. The National Coffee Association, which represents the US coffee industry told CNN that it was 'highly irresponsible to mislead Americans about the safety of their favorite beverage.' 'Decades of independent scientific evidence show that coffee drinkers live longer, healthier lives,' NCA President and CEO William 'Bill' Murray said in an email. The Clean Label Project measures levels of heavy metals, pesticides and plasticizers in food and consumer products. The organization also checks to see whether the tested products' labels list those contaminants. To do the testing, Clean Label obtained samples of coffee from 45 popular brands — which they did not name. Coffee beans were grown in Brazil, Colombia, Costa Rica, Ethiopia, Guatemala, Kenya, Peru and Hawaii. A certified lab conducted over 7,000 tests looking for pesticides, including glyphosate; heavy metals such as lead, mercury, arsenic and cadmium; mycotoxins, which are toxic chemical compounds produced by some molds that grow on crops; and phthalates, a plasticizer found in consumer products such as food wrapping, food storage containers, shampoo, makeup, perfume and children's toys. The tests found scant glyphosate, but 'significant' amounts of aminomethylphosphonic acid, or AMPA, a byproduct of glyphosate as it breaks down in the environment, according to the report. The half-life of AMPA is longer than that of glyphosate, which means it can persist in the environment and is easily absorbed by plants from soil and water. In addition, AMPA has been shown to damage cellular DNA in prostate cells and cause an increased risk of liver inflammation and metabolic disorders in young adults. Testing found organic coffees bested conventional coffees in total amounts of contaminants, but there was one oddity — there were levels of AMPA in all of the 12 organic coffees tested. Of the 45 samples of conventionally grown coffees, only 29 tested positive for aminomethylphosphonic acid, according to the report. While certified organic coffee growers cannot use pesticides like glyphosate, it's possible for organic fields to be contaminated by runoff from neighboring conventional farms, Hamilton said. 'Still, the detection of AMPA in 100% of organic samples we tested is definitely a wake-up call,' she said. 'We definitely need stronger safeguards and greater transparency in our food system.' Levels of heavy metals depended on where the coffee was grown. Africa has some of the lowest levels of heavy metals, while the highest were found in Hawaiian coffee. Hawaii, however, is a volcanic island and therefore expected to have more significant levels of heavy metals in the soil. An analysis also found 100% of the tested coffee samples contained small amounts of acrylamide, a colorless, odorless chemical formed when certain foods are cooked at high temperatures, such as when frying, baking and roasting. Acrylamide has been linked to cancer in animals when they are exposed to extremely high doses. However, the chemical is not thought to be toxic to humans at small levels of consumption. Despite that, the US Food and Drug Administration has advised manufacturers to attempt to lower levels in the food supply. Clean Label's testing found levels of acrylamide varied with the degree of roasting of coffee beans. The highest levels of acrylamide were found in medium roasts, followed by light roasts and dark roasts. 'The dark coffees are the best choice because they are roasted at lower temperatures for a longer period of time so acrylamide levels don't rise,' Hamilton explained. 'The light coffees are roasted minimally, so here too, acrylamide levels don't build up. 'However, medium roasts have the higher levels of acrylamide because they are roasted at higher temperatures long enough to darken the beans,' she said. What could a coffee lover take away from the testing? 'When you decide which coffee to buy, choose darker or the lightest roasts in bags or pods and consider where coffee is grown, which can impact the levels of heavy metals,' Hamilton said. 'But I want to stress that it's important to put these findings into context,' she added. 'Caffeinated coffee is still one of the cleanest product categories we've ever tested. 'Our report isn't meant to raise alarm or keep consumers from drinking coffee, but rather to empower people on how to choose the cleanest, safest cup of coffee.' Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
